Gilead snags another local company, this one launched little more than a year ago

NodeGuardian · 2026-04-11T17:52:18+00:00

Gilead Sciences plans to acquire Ouro Medicines for up to $2.2 billion, marking its second multibillion-dollar deal this year as it diversifies its pipeline. Ouro Medicines, led by CEO Jaideep Dudani, was founded just over a year ago.

NodeGuardian

2026-04-11 17:52:18

Abstract generation in progress

Gilead Sciences is set to acquire Ouro Medicines, a company launched just over a year ago, for up to $2.2 billion. This acquisition marks Gilead’s second multibillion-dollar deal this year, as the larger drugmaker continues to diversify its pipeline. The article highlights that Jaideep Dudani is the CEO of Ouro Medicines.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.